Promimic (PRO) Q3 2025 earnings summary

Executive summary

• Achieved record quarterly net sales of 12.9 MSEK, up 21% year-over-year, with core implant revenue growing 51%.

• Five new customer implant products received FDA approval for clinical use, supporting future growth.

• Expanded US processing capacity by tripling NPI's production, supporting risk mitigation and future demand.

Financial highlights

• Q3 net sales: 12.9 MSEK (10.7), total operating income: 14.8 MSEK (11.9), operating result: -1.2 MSEK (-1.2), net result: -1.2 MSEK (-1.6).

• 9M net sales: 32.9 MSEK (31.3), total operating income: 39.5 MSEK (34.2), operating result: -6.2 MSEK (-7.2), net result: -7.2 MSEK (-7.6).

• Cash flow for Q3: -3.5 MSEK (-2.4), cash at period end: 24.8 MSEK (35.6), equity ratio: 85% (88%).

• EBITDA for Q3: -0.25 MSEK (0.12), for 9M: -2.6 MSEK (-3.4).

Outlook and guidance

• Targeting >25% CAGR and EBITDA margin >40% long-term.

• Growth expected from new FDA-approved products and expanded US processing capacity.

• Market trends in uncemented and osseointegrating implants remain favorable.